

**HAI DUONG PHARMACEUTICAL
MEDICAL MATERIALS JSC.**

SOCIALIST REPUBLIC OF VIETNAM
Independence – Freedom - Happiness

No: 480/2026-CV

*Re: Explanation of the fluctuation in Revenue
and Profit after CIT in Quarter 1/2026 by
over 10%.*

Hai Phong, April 25th, 2026

To: - State Securities Commission of Vietnam(SSC)
- Hanoi Stock Exchange(HNX)

- **Company name:** Hai Duong Pharmaceutical Medical Materials JSC
- **Enterprise Registration Certificate:** 0800011018
- **Address:** No. 102 Chi Lang Street, Thanh Dong Ward, Hai Phong City
- **Tel:** 02203853848 **Fax:** 02203853848

Pursuant to Clause 4, Article 14 of Circular No. 96/2020/TT-BTC dated November 16th, 2020, of the Minister of Finance on information disclosure in the securities market, Hai Duong Pharmaceutical Medical Materials JSC would like to provide the following explanation regarding the Financial Statements in Quarter 1/2026:

1. Sales Revenue

According to the Income Statement in Quarter 1/2026, the revenue increased by **19.74%** compared to the same period in 2025, specifically:

Unit: VND

Indicator	Quarter 1, 2026	Quarter 1, 2025	Increase%
Revenue	193.459.322.603	161.570.158.355	19,74%

Explanation:

Products manufactured on the EU-GMP production line have been well received by both domestic and international markets, resulting in increased sales of manufactured goods. Additionally, trading goods supplied to medical examination and treatment facilities also experienced strong growth. These are the key factors contributing to the significant revenue increase in Quarter 1/2026 compared to Quarter 1/2025. Details by category are as follows:

- The revenue of Manufactured goods (domestic and export) reached 146,507,590,815 VND, increased 15,514,814,911 VND. Growth rate: 11.84%



- The revenue of trading goods and services reached 46,951,731,788 VND, increased 16,374,349,337 VND. Growth rate: 53.55%

2. Profit after Corporate Income Tax

According to the Income Statement in Quarter 1/2026, Profit after Corporate Income Tax (CIT) increased by **26.94%** compared to the same period in 2025, specifically:

Unit: VND

Indicator	Quarter 1, 2026	Quarter 1, 2025	Increase%
Profit after Corporate Income Tax	16.888.373.130	13.304.745.502	26,94%

Explanation:

Sales revenue increased by 19.74%, equivalent to 31,889,164,248 VND, leading to an increase in gross profit of 5,848,932,648 VND compared to Quarter 1/2025, with a growth rate of 9.75%. This is the primary driver for the increase in profit before corporate income tax.

Not only the revenue increased, in Quarter 1/2026, but the Company also effectively managed financial expenses, selling expenses, and administrative expenses. As a result, these costs only increased by 1,378,345,368 VND, equivalent to 3.2%, which is lower than the gross profit growth rate.

Based on the above factors, Profit after Corporate Income Tax in Quarter 1/2026 increased by **26.94%** compared to Quarter 1/2025.

All contents of the Financial Statements for Quarter 1/2026 have been published on the Company's website: **hdpharma.vn**

We hereby commit that the above-published information is true and accurate, and we take full legal responsibility before the law for the disclosed information.

Recipients:

- As stated above;
- Archive

HAI DUONG PHARMACEUTICAL MEDICAL MATERIALS JSC.

GENERAL DIRECTOR



TỔNG GIÁM ĐỐC

ĐSCK I: NGUYỄN THỊ TÚ ANH